ScholarIQanswers from OpenAlex & ORCID
Margarita Majem
ResearcherPublications, citations & collaboration network
Margarita Majem is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Margarita Majem have?
ScholarIQindexed works
Margarita Majem has 570 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Margarita Majem have?
ScholarIQcitation count
Margarita Majem has 24,725 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Margarita Majem?
ScholarIQh-index
Margarita Majem has an h-index of 57 in OpenAlex.
What is the i10-index of Margarita Majem?
ScholarIQi10-index
Margarita Majem has an i10-index of 163 in OpenAlex.
What is the ORCID of Margarita Majem?
ScholarIQorcid
The ORCID for Margarita Majem is on the source record.
What is the OpenAlex record for Margarita Majem?
ScholarIQopenalex
The OpenAlex for Margarita Majem is on the source record.
What are the most-cited papers on Margarita Majem?
ScholarIQmost cited works
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled‐Filhart, Edward B. Garon
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi, Se‐Hoon Lee, Shugeng Gao, Ke‐Neng Chen, Christophe Dooms, Margarita Majem, E. Eigendorff, Gastón Lucas Martinengo, Olivier Bylicki, Delvys Rodríguez‐Abreu, Jamie E. Chaft, Silvia Novello, Jing Yang, Steven M. Keller, Ayman Samkari, Jonathan Spicer
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood Goss, Chun‐Ming Tsai, Frances A. Shepherd, Lyudmila Bazhenova, Jong Seok Lee, Gee‐Chen Chang, Lucio Crinò, Miyako Satouchi, Quincy S. Chu, Toyoaki Hida, Ji‐Youn Han, Óscar Juan, Frank Dunphy, Makoto Nishio, Jin‐Hyoung Kang, Margarita Majem, Helen Mann, Mireille Cantarini, Serban Ghiorghiu, Tetsuya Mitsudomi
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohé, Jie Wang, Jonathan W. Goldman, Shun Lü, Wu‐Chou Su, Filippo de Marinis, Frances A. Shepherd, Ki Hyeong Lee, Nhieu Thi Le, Arunee Dechaphunkul, Dariusz M. Kowalski, Lynne Poole, Ana Bolanos, Yuri Rukazenkov, Yi‐Long Wu